Skip to main content
. 2022 Sep 6;40(5):876–884. doi: 10.1002/hon.3072

FIGURE 2.

FIGURE 2

Survival of Adult T‐cell leukemia/lymphoma (ATL) patients stratified according to CCR7 gene alterations. (A) Overall survival (OS) of all ATL patients enrolled in the study (n = 223). The median OS was 1.8 years (95% confidence interval [CI], 1.3–2.1 years). (B) OS according to CCR7 alterations (with CCR7 alterations [+] compared with no alterations [−]; hazard ratio [HR], 1.034, 95% CI, 0.610–1.752). (C) Survival of ATL patients from the day of allogeneic hematopoietic stem cell transplantation (HSCT) (n = 54). The median survival was 1.4 years (95% CI, 0.0–2.9 years). (D) Survival from the day of allogeneic HSCT according to CCR7 alterations (with CCR7 alterations [+] compared to those without [−]; HR, 0.691, 95% CI, 0.208–2.293). (E) Survival of ATL patients receiving mogamulizumab but not allogeneic HSCT (n = 84). The median survival from the first dose of mogamulizumab was 1.4 years (95% CI, 0.8–2.1 years). (F) Survival from the first dose of mogamulizumab according to CCR7 alterations (with CCR7 alterations [+] vs. without [‐]; HR, 2.372, 95% CI, 1.119–5.027). (G) Survival from the first dose of mogamulizumab according to CCR4 alterations (with CCR4 alterations [+] compared to without [−]; HR, 0.538, 95% CI, 0.266–1.087). (H) Survival from the first dose of mogamulizumab according to CCR4 and CCR7 alterations (with CCR4 alterations [+] but without CCR7 alterations [−] compared with the others; HR, 0.400, 95% CI, 0.178–0.901)